Slide 1: Targeted Regeneration Corporate Presentation
Targeted Regeneration Corporate Presentation April 1, 2024 Exhibit 99.2
Slide 2: Legal Disclaimers
Legal Disclaimers © 2024 Surrozen, Inc. This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of
Slide 3: Investment Highlights
Investment Highlights © 2024 Surrozen, Inc. Innovator in modulating the Wnt pathway for tissue regeneration; attractive, novel treatment strategy for large markets with high unmet need First-in-class SZN-043 antibody in Phase 1 – Phase 1b dose selected for advancement Phase 1b efficacy data expected
Slide 4: Our Discoveries Enabled the Pursuit of Selectively Harnessing the Wnt Pathway for Regeneration
First synthetic, soluble Wnt mimetics Multivalent binding required to confer potency and selectivity Multivalent bi-specific antibody formats for optimal activity R-Spondin mimetic technology and potential role in regeneration Fzd4 agonism therapeutic potential in retinopathies Discoveries form the
Slide 5: Wnt Biology Drives R&D Pipeline
Wnt Biology Drives R&D Pipeline Program Indication Research Preclinical Phase 1 Phase 2 Phase 3 Partnerships Status SZN-043 Severe Alcohol-Associated Hepatitis Phase 1a study complete; Initiating Phase1b study SZN-413 Retinopathies © 2024 Surrozen, Inc. Additional preclinical programs in cornea, ret
Slide 6: Momentum Building with Significant Catalysts/Milestones
© 2024 Surrozen, Inc. 2024 2024 2025 Momentum Building with Significant Catalysts/Milestones Program Indication SZN-043 Severe Alcohol-Associated Hepatitis Ph1 Safety Initiate/enroll Phase 1b Ph1b POC efficacy; Initiate Ph2/Ph3 Initiate P2 SZN-413 ( ) Retinopathies Preclinical Potential $10M Milesto
Slide 7: Liver Program SZN-043
Liver Program SZN-043 Hepatocyte-Targeted R-spondin Mimetic (SWEETS) for Severe Alcohol-Associated Hepatitis Mutated RSPO2 Anti-ASGR1 IgG Effector-less hIgG1
Slide 8: SZN-043 Program Summary
SZN-043 Program Summary Antibody Targeted to Liver that Mimics Endogenous R-Spondin to Mediate Liver Regeneration © 2024 Surrozen, Inc. Phase 1b study commencing in early 2024 in severe alcohol-associated hepatitis (SAH) Potential for Breakthrough Therapy Designation; Phase 2/3 adaptive trial design
Slide 9: SZN-043 Potential to Transform Patient Outcomes in SAH
SZN-043 Potential to Transform Patient Outcomes in SAH Well Validated Endpoints; Potential Rapid Pathway to Approval; Unmet Medical Need Our Solution Selectivity achieved through inclusion of ASGR1 binder MOA: SZN-043 designed to addresses underlying pathophysiology Hepatocyte proliferation & Wnt si
Slide 10: SZN-043 Phase 1a Clinical Trial Summary
SZN-043 Phase 1a Clinical Trial Summary Moving Forward with 0.5mg/kg to 1.5mg/kg in Phase Ib © 2024 Surrozen, Inc. Safety & PK Adverse events assessed to be drug related were mild to moderate, all resolving during the study In healthy volunteers, a few asymptomatic and transient transaminase elevati
Slide 11: PD: Breath Test Results Indicate Activation Of Wnt Pathway In Cirrhotics
PD: Breath Test Results Indicate Activation Of Wnt Pathway In Cirrhotics Test Measures Metabolism of Methacetin by Wnt Pathway Gene (CYP2A1) © 2024 Surrozen, Inc.
Slide 12: SZN-043 Demonstrated Effects on Liver Function in Cirrhotics
SZN-043 Demonstrated Effects on Liver Function in Cirrhotics Improved Portal Hepatic Filtration Rate and Disease Severity Index © 2024 Surrozen, Inc. HepQuant test measures cholate clearance, a liver specific function that quantifies liver function Demonstrated improved portal hepatic filtration rat
Slide 13: Mean (SD) Serum SZN-043 Concentrations Following an IV dose
Mean (SD) Serum SZN-043 Concentrations Following an IV dose 1 mg/kg 3 mg/kg 0.5 mg/kg X2 1 mg/kg X2 0.5 mg/kg cirr AUC (µg-day/mL) 3.2 (1.9) 34.9 (6.6) 2.09 (1.81) 6.03 (1.47) 0.475 (0.145) CL (ml/day/kg) 454 (324) 89.0 (19.8) 734 (450) 352 (104) 1110 (310) Terminal half-life (Days) 0.737 (0.218) 3.
Slide 14: SZN-043: Severe Alcohol-Associated Hepatitis | Fast Path to POC
SZN-043: Severe Alcohol-Associated Hepatitis | Fast Path to POC © 2024 Surrozen, Inc. Phase 1A Phase 1B Phase 2/3 Pop Healthy Volunteers Chronic Liver Dx SAH SAH N 36 18 - 30 ~300 Design SAD/MAD Placebo-controlled SAD/MAD Open-label, SOC Controlled TBD Countries New Zealand Single-Site Multi-country
Slide 15: SZN-043 In Vivo Effects
Ammonia SZN-043 In Vivo Effects Liver Specific Proliferation, Functional Improvement, Fibrosis Regression Compelling Preclinical Data >25 preclinical studies conducted Selectively activates Wnt Signaling in Hepatocytes Selectively Induces hepatocyte proliferation Rapidly improves liver function Redu
Slide 16: SZN-413 Program
SZN-413 Program
Slide 17: SZN-413 Program Summary
SZN-413 Program Summary Antibody Targeted to Fzd4 which is Known to Mediate Proper Function of Retinal Vascular Endothelial Cells © 2024 Surrozen, Inc. Novel mechanism for treatment of retinopathies that can directly reduce leakage and potentially reduce VEGF production Multiple preclinical models o
Slide 18: SZN-413: Potential for Full Reversal of Patient's Retinopathy
SZN-413: Potential for Full Reversal of Patient’s Retinopathy SZN-413 Vehicle Aflibercept Retinal Vascular Program SZN-413 addresses retinal non-perfusion and vascular leakage simultaneously Fzd4/Norrin signaling plays critical role in maintenance of retinal vasculature integrity SZN-413 (Fzd4/LRP5
Slide 19: Cornea and Retinal Programs
Cornea and Retinal Programs
Slide 20: Surrozen Wnt Agonist Significantly Reduces Corneal Thickness in Model of Corneal Dystrophy
Surrozen Wnt Agonist Significantly Reduces Corneal Thickness in Model of Corneal Dystrophy © 2024 Surrozen, Inc. Rationale Fuchs’ leads to vision loss and discomfort; 4% of adults >40 have signs of FECD in U.S.1 Need for novel therapies to slow progression or improve surgical outcomes Wnt receptors
Slide 21: Potential Approaches for Wnt in Dry AMD
Potential Approaches for Wnt in Dry AMD Wnt Activation Could Impact Disease Through Two Mechanisms RPE Photoreceptor Wnt/β-catenin signaling Protection/Regeneration 1. RPE Regeneration 2. Photoreceptor Regeneration © 2024 Surrozen, Inc.
Slide 22: Momentum Building with Significant Catalysts/Milestones
© 2024 Surrozen, Inc. Program Indication SZN-043 Severe Alcohol-Associated Hepatitis Ph1 Safety Initiate/Enroll Ph1b Ph1b POC Efficacy; Initiate Ph2/Ph3 Initiate P2 SZN-413 ( ) Retinopathies Preclinical Potential $10M Milestone Cornea Fuchs’ Endothelial Corneal Dystrophy Candidate Nomination IND/Ph1
Slide 23: Appendix
Appendix © 2024 Surrozen, Inc.
Slide 24: Glossary
Glossary ADA – Anti-drug antibodies AE – Adverse events (SAE – serious AE) AH – Alcohol-associated hepatitis ALP – Alkaline Phosphatase ALT – Alanine Aminotransferase AMD – Age-related macular degeneration ASGR1 – Asiaglycoprotein receptor 1 AST – Aspartate aminotransferase AT1/AT2 – Alveola